Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Cuba has been experiencing a steady growth in recent years.
Customer preferences: Cuban customers have been increasingly turning towards Anti-Coagulants due to the rise in cardiovascular diseases and the aging population. The convenience of oral Anti-Coagulants over injectable ones has also contributed to the growth of the market.
Trends in the market: The Anti-Coagulants market in Cuba has been witnessing a shift towards novel oral Anti-Coagulants (NOACs) from traditional Anti-Coagulants such as warfarin. This can be attributed to the lower risk of bleeding and the reduced need for regular monitoring with NOACs. The market has also been witnessing an increase in the availability of generic Anti-Coagulants, which has made them more affordable and accessible to the general population.
Local special circumstances: Cuba's healthcare system is heavily subsidized by the government, and access to healthcare is considered a fundamental right. The government has been investing in the healthcare sector, which has led to an increase in the availability of Anti-Coagulants in the market. The country's healthcare system is also heavily focused on prevention, which has led to an increase in the demand for Anti-Coagulants.
Underlying macroeconomic factors: Cuba's economy has been experiencing a slow but steady growth over the past few years. The government has been implementing economic reforms to attract foreign investment and boost the economy. This has led to an increase in the availability of Anti-Coagulants in the market, as foreign pharmaceutical companies have been entering the market. The aging population and the rise in cardiovascular diseases have also contributed to the growth of the Anti-Coagulants market. In conclusion, the Anti-Coagulants market in Cuba has been experiencing a steady growth due to the rise in cardiovascular diseases, the aging population, and the availability of generic Anti-Coagulants. The shift towards NOACs and the government's focus on prevention have also contributed to the growth of the market. The government's investment in the healthcare sector and the country's slow but steady economic growth have led to an increase in the availability of Anti-Coagulants in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
